The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...
In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...
Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...
A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.
For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...
There are additional considerations that physicians need to consider when prescribing GLP-1s to patients with disabilities or ...
Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse ...
A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming bipartisan support for Medicare and Medicaid coverage of glucagon-like peptide ...
At the heart of this discovery lies the role of glucagon-like peptide-1 (GLP-1), a hormone known for its involvement in ...
When her consultant offered 20st Sarah a brand new injection called Ozempic that promised to treat her diabetes and help her ...
Here are some practical guidelines and considerations for safely exercising while on GLP-1 medications. Text Callout : Key Takeaways - Exercising on GLP-1s How GLP-1 Medications Affect the Body ...
14h
GlobalData on MSNEikon raises almost $351m to advance cancer candidates through the clinicEikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results